Newly found 'immune organ' inside skull directs brain defense
medicalxpress - Researchers at Washington University School of Medicine in St. Louis have discovered lymph node-like structures in the skull bone marrow of mice for the first time and demonstrated that they act as rapid first responders against brain cancer before distan…
AI Summary: Scientists discovered organized immune cell hubs within the skull that communicate directly with the brain, revealing a previously overlooked pathway for neuroimmune surveillance. The structures appear to coordinate responses to infection and injury, offering fresh targets for neurological disease therapies and a neat explanation for why the brain sometimes seems to have its own security detail.
New brain cell formation stalls in adults with depression, study shows
medicalxpress - Findings from a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons suggest that the trickle of neurons created in the adult hippocampus could be instrumental in preventing depression. Most of the brain's 100 billion…
AI Summary: Studies report that adults with major depressive disorder show reduced generation of new neurons in the hippocampus, suggesting impaired adult neurogenesis may underlie persistent symptoms. Findings provide a biological clue to treatment resistance and point toward therapies that could restore brain plasticity — promising, and mildly depressing for depression itself.
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Frank Vinluan / medcitynews - Ultragenyx Pharmaceutical’s Genglycos received accelerated FDA approval for glycogen storage disease type Ia, an inherited enzyme deficiency. It’s also the first approved gene therapy for Ultragenyx, which specializes in rare disease treatments. The post …
AI Summary: Ultragenyx received FDA approval for a gene therapy, marking the first approved treatment for that particular ultra‑rare disorder. The decision provides a regulated therapeutic option for patients previously without approved care, highlighting the evolving regulatory willingness to greenlight transformative but small‑population medicines.
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
oncodaily - Treatment intensification with androgen receptor pathway inhibitors has become central to the management of metastatic hormone-sensitive prostate cancer (mHSPC). However, as patients remain on these therapies for years, longer follow-up […]
AI Summary: Long-term follow-up from ENZAMET shows enzalutamide continues to deliver a substantial overall survival benefit at eight years for patients with metastatic hormone-sensitive prostate cancer. The durable outcome cements enzalutamide’s role in combination androgen-deprivation strategies, giving patients and clinicians a proven option — not a cure, but progress that actually lasts.